Skip to main content
Home > BC Innovations > Targets & Mechanisms

Chronological Index of : Targets & Mechanisms

 Current Issue
  • Figure: Cleanup crew

    Forty Seven and counting Targets & Mechanisms Cleanup crew In a pair of Nature and Science Translational Medicine studies, Stanford University teams have shown blocking the "don't eat me" cell surface protein CD47 …

    Published on 8/25/2016
  • Table: BioCentury Product Profile

    Forty Seven and counting Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product CD47-blocking mAb CD47-blocking mAb or fusion protein Concept Blocking CD47 can …

    Published on 8/25/2016
  • Table: Chasing CD47

    Forty Seven and counting Targets & Mechanisms Chasing CD47 At least six companies are developing compounds to block the anti-phagocytic cell surface protein CD47, either with CD47-targeting antibodies or with …

    Published on 8/25/2016
  • Forty Seven and counting

    Stanford and Forty Seven Inc. count up new indications for CD47 blockade

    With CD47 gaining status as the go-to target in oncology, a pair of Stanford studies suggest the target could extend to cardiovascular disease, transplant biology and more.

    Published on 8/25/2016
  • Box: A cut too far

    Niche for the aged Targets & Mechanisms A cut too far For effective wound repair, muscle stem cells - known as satellite cells - must spring into action and then return to quiescence. A study published last month …

    Published on 8/11/2016
  • Figure: Healing young again

    Niche for the aged Targets & Mechanisms Healing young again A pair of Nature Medicine studies have identified a receptor, integrin β1, and one of its ligands, fibronectin, which could be targeted to boost muscle …

    Published on 8/11/2016
  • Niche for the aged

    Targeting integrin β1 or fibronectin for muscle repair in the aged

    A pair of studies identified integrin β1 and fibronectin as two sides of the same coin for improving post-injury muscle regeneration in the elderly.

    Published on 8/11/2016
  • Cereblon ambition

    A structural motif could help Celgene find new targets to send to the proteasome

    Celgene has identified a structural motif at the heart of thalidomide's MOA, and is looking for more proteins with the feature that could pave a path to new drugs.

    Published on 8/4/2016
  • Figure: Good riddance to new rubbish

    Cereblon ambition Targets & Mechanisms Good riddance to new rubbish Celgene Corp. (NASDAQ:CELG) hopes to extend the degradation-based mechanism of action of thalidomide and its analogs, known as imids, to new …

    Published on 8/4/2016
  • Table: BioCentury Product Profile

    Cereblon ambition Targets & Mechanisms BioCentury Product Profile BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product A platform to find substrates for degradation induced by thalidomide analogs (imids) Concept…

    Published on 8/4/2016
  • Figure: Maverick microglia

    Effectorless efficacy Targets & Mechanisms Maverick microglia Researchers at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) and AC Immune S.A. have shown that using standard mAbs to treat CNS diseases may …

    Published on 7/28/2016
  • Table: BioCentury Product Profile

    Effectorless efficacy Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product An anti-tau mAb incapable of binding microglia Concept Reduce tau pathology without …

    Published on 7/28/2016
  • Effectorless efficacy

    How Genentech is making mAbs safer for CNS diseases

    By designing therapeutic mAbs to fly under the radar of brain microglial cells, Genentech is making the modality safer for treating CNS diseases without sacrificing efficacy.

    Published on 7/28/2016
  • Figure: Crossing paths

    Making sense of sensors Targets & Mechanisms Crossing paths Since TLR9 was first identified as an innate immune receptor that detects microbial DNA and helps initiate a response to infection two decades ago, new …

    Published on 7/28/2016
  • Figure: Some like it hot

    Making sense of sensors Targets & Mechanisms Some like it hot Activation of nucleic acid sensors such as TLR9 can make so-called "cold" immunosuppressed tumors into "hot" ones that become infiltrated with antitumor…

    Published on 7/28/2016
  • Making sense of sensors

    Targeting nucleic acid sensors makes sense for cancer

    While TLRs have put nucleic acid sensors on the map, newer class members STING and RIG-I are raising interest as alternatives in immuno-oncology.

    Published on 7/28/2016
  • Figure: Triggering AD

    AChE revisited Targets & Mechanisms Triggering AD Neuro-Bio Ltd. has identified a peptide derived from AChE that is overexpressed in the brain centers that degenerate first in Alzheimer's disease (AD), and has …

    Published on 6/30/2016
  • Table: BioCentury Product Profile

    AChE revisited Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product A compound that inhibits binding of an AChE-derived peptide to CHRNA7 Concept Prevent …

    Published on 6/30/2016
  • AChE revisited

    Why Neuro-Bio thinks it's time to revisit the role of AChE in AD

    With a new take on an old target, Neuro-Bio believes a developmental form of AChE holds the key to slowing neurodegeneration in Alzheimer's disease.

    Published on 6/30/2016
  • Hide and seek

    A two-part strategy for chasing dormant breast cancer cells out of hiding

    A two-part mechanism discovered at Duke explains how breast cancer cells enter and hide in bone marrow, and suggests GlycoMimetics' next clinical compound could be used to flush them out.

    Published on 6/23/2016
  • Figure: Bad to the bone

    Hide and seek Targets & Mechanisms Bad to the bone A Duke University team has shown how breast cancer cells that have left the primary tumor invade the bone marrow to create dormant micrometastases capable of …

    Published on 6/23/2016
  • Table: BioCentury Product Profile

    Hide and seek Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product GMI-1359, a dual inhibitor of E selectin and CXCR4 Concept Drive dormant micrometastases out of…

    Published on 6/23/2016
  • Vedanta's horizons

    How microbiome company Vedanta is expanding its microbiome platform

    With a $50 million series B round and new technology, Vedanta is expanding its microbiome platform to turn up or down inflammation to fit the indication.

    Published on 6/16/2016
  • Figure: Axis of diabetes

    The Finnish connection Targets & Mechanisms Axis of diabetes An international research group has found that differences between the standards of living in Russia, Estonia and Finland are linked to differences in …

    Published on 6/16/2016
  • Figure: Battle of the bugs

    The Finnish connection Targets & Mechanisms Battle of the bugs In a study in Cell, an international consortium of researchers showed that susceptibility to Type I diabetes was affected by regional differences in …

    Published on 6/16/2016

< Previous   1  2  3  4  5  Next >

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993